Abeona Therapeutics Inc vs Koninklijke Philips NV — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Koninklijke Philips NV trades at $26.99 (market cap $26.58B). The key difference: Koninklijke Philips NV is far larger — about 63.1× Abeona Therapeutics Inc's market cap, and Koninklijke Philips NV pays a 3.75% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | PHG | |
|---|---|---|
Market Cap | $421.19M | $26.58B |
Sector | Health | Health |
52-Week High | $7.45 | $32.91 |
52-Week Low | $4.17 | $25.02 |
Enterprise Value | $276.10M | $33.13B |
Dividend Yield | — | 3.75% |
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →